Novartis AG Asset Resilience Ratio
Novartis AG asset resilience ratio. Novartis AG (NVSN) has an Asset Resilience Ratio of 0.08% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See NVSN days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Novartis AG (2014–2025)
Asset resilience ratio of Novartis AG from 2014 to 2025. This chart shows how Novartis AG's Asset Resilience Ratio has changed over time. Read debt load of Novartis AG for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Novartis AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see NVSN asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | MX$0.00 | 0% |
| Short-term Investments | MX$100.00 Million | 0.08% |
| Total Liquid Assets | MX$100.00 Million | 0.08% |
Asset Resilience Insights
- Limited Liquidity: Novartis AG maintains only 0.08% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Novartis AG Industry Peers by Asset Resilience Ratio
Compare Novartis AG's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.
SHE:301096 |
Drug Manufacturers - General | 1.58% |
|
GuangYuYuan Chinese Herbal Medicine Co Ltd
SHG:600771 |
Drug Manufacturers - General | 1.97% |
|
Roche Holding AG
SW:ROG |
Drug Manufacturers - General | 15.37% |
|
Sanofi
F:SNW2 |
Drug Manufacturers - General | 0.37% |
|
Sichuan Kelun Pharmaceutical Co Ltd
SHE:002422 |
Drug Manufacturers - General | 8.05% |
|
Grifols S.A
F:G0FB |
Drug Manufacturers - General | 0.12% |
|
TTK Healthcare Limited
NSE:TTKHLTCARE |
Drug Manufacturers - General | 68.81% |
|
Eli Lilly and Company
NYSE:LLY |
Drug Manufacturers - General | 0.13% |
Novartis AG Asset Resilience Ratio by Year (2014–2025)
Novartis AG asset resilience ratio by year from 2014 to 2025. The table below shows the annual Asset Resilience Ratio data for Novartis AG.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.09% | MX$98.00 Million ≈ $5.64 Million |
MX$110.95 Billion ≈ $6.39 Billion |
-1.76pp |
| 2024-12-31 | 1.85% | MX$1.89 Billion ≈ $108.89 Million |
MX$102.25 Billion ≈ $5.88 Billion |
+1.28pp |
| 2023-12-31 | 0.57% | MX$569.00 Million ≈ $32.75 Million |
MX$99.94 Billion ≈ $5.75 Billion |
-9.15pp |
| 2022-12-31 | 9.72% | MX$11.41 Billion ≈ $656.82 Million |
MX$117.45 Billion ≈ $6.76 Billion |
-2.20pp |
| 2021-12-31 | 11.92% | MX$15.71 Billion ≈ $903.89 Million |
MX$131.79 Billion ≈ $7.58 Billion |
+10.47pp |
| 2020-12-31 | 1.44% | MX$1.91 Billion ≈ $109.63 Million |
MX$132.06 Billion ≈ $7.60 Billion |
+1.16pp |
| 2019-12-31 | 0.28% | MX$334.00 Million ≈ $19.22 Million |
MX$118.37 Billion ≈ $6.81 Billion |
-1.57pp |
| 2018-12-31 | 1.85% | MX$2.69 Billion ≈ $154.98 Million |
MX$145.56 Billion ≈ $8.38 Billion |
+1.38pp |
| 2017-12-31 | 0.47% | MX$625.00 Million ≈ $35.97 Million |
MX$133.08 Billion ≈ $7.66 Billion |
-0.12pp |
| 2016-12-31 | 0.59% | MX$770.00 Million ≈ $44.31 Million |
MX$130.12 Billion ≈ $7.49 Billion |
+0.11pp |
| 2015-12-31 | 0.48% | MX$630.00 Million ≈ $36.26 Million |
MX$131.56 Billion ≈ $7.57 Billion |
+0.09pp |
| 2014-12-31 | 0.39% | MX$483.00 Million ≈ $27.80 Million |
MX$125.39 Billion ≈ $7.22 Billion |
-- |
About Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic … Read more